Discontinuation report NOVOLIN GE NPH PENFILL
Report ID | 240234 |
Drug Identification Number | 02024268 |
Brand name | NOVOLIN GE NPH PENFILL |
Common or Proper name | NOVOLIN GE NPH PENFILL |
Company Name | NOVO NORDISK CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | INSULIN ISOPHANE HUMAN BIOSYNTHETIC |
Strength(s) | 100UNIT |
Dosage form(s) | SUSPENSION |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | 5 |
ATC code | A10AC |
ATC description | INSULINS AND ANALOGUES |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2025-12-31 |
Actual discontinuation date | |
Remaining supply date | 2025-12-31 |
Discontinuation status | To be discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 101-2476 ARGENTIA ROAD MISSISSAUGA, ONTARIO CANADA L5N 6M1 |
Company contact information | 1 800 465 4334 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2024-10-15 | French | Compare |
v1 | 2024-10-15 | English | Compare |
Showing 1 to 2 of 2